Analytical Data
-
基因名
FLT3
- Application
-
别名
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q00342
-
表达区间
Lys335~Ser544
-
分子量
27kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FLT3 (Fms-like tyrosine kinase 3) is a crucial receptor tyrosine kinase that plays a significant role in hematopoiesis and is predominantly expressed in hematopoietic stem and progenitor cells. Mutations and overexpression of FLT3 are commonly associated with various hematological malignancies, particularly acute myeloid leukemia (AML), where FLT3-ITD (internal tandem duplications) mutations are linked to poor prognosis and increased disease aggressiveness. The study of FLT3 recombinant proteins serves multiple purposes, including elucidating the molecular mechanisms of FLT3 signaling pathways, exploring its role in leukemogenesis, and facilitating the development of targeted therapies. Recombinant FLT3 proteins allow researchers to investigate receptor-ligand interactions, assess enzymatic activity, and screen potential inhibitors in vitro. Furthermore, understanding the structural and functional properties of FLT3 proteins can pave the way for the design of FLT3 inhibitors, which have shown promise in clinical settings. The ongoing research aims to improve therapeutic outcomes for AML patients by targeting FLT3 mutations, therefore highlighting the importance of FLT3 recombinant proteins in both basic and applied cancer research.
